Sagility Limited reported strong financial results for the second quarter and first half of FY27, ending September 30, 2026. Revenue saw a 22.5% year-over-year growth to ₹20,321 million for the quarter. The Board of Directors also approved an interim dividend of ₹0.15 per equity share, signaling confidence and commitment to shareholder returns.
Sagility’s Q2 FY27 Performance Highlights
Sagility Limited, a prominent healthcare operations partner, announced robust financial results for the quarter and half-year ended September 30, 2026. The company demonstrated strong performance, with revenue from operations reaching ₹20,321 million for the second quarter of FY27, marking a significant 22.5% year-over-year growth (12.2% in constant currency). Organic growth also remained strong at 22.2%.
Key Financials and Dividend Declaration
In the first half of FY27, Sagility’s revenue stood at ₹39,956 million, a 25.0% YoY increase. Adjusted EBITDA for the quarter was ₹5,353 million, reflecting a 23.0% growth, and Adjusted PAT was ₹3,254 million, up 8.1% YoY. Demonstrating its commitment to shareholders, the Board of Directors approved an interim dividend of ₹0.15 per equity share. This interim dividend, with a record date of October 30, 2026, is expected to be disbursed on or before November 21, 2026.
Business and Acquisition Updates
The company also highlighted strategic business wins, securing $40.2 million of ACV from new and existing clients. The integration of the CareSeed acquisition has expanded its client base to 105 active groups. Furthermore, Sagility announced the acquisition of Chirok Health LLC, a U.S.-based healthcare services company, aimed at accelerating growth in the provider segment by enhancing its clinical documentation integrity and revenue cycle management capabilities.
Source: BSE
